These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28836341)

  • 21. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
    J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study.
    Zhao L; Yang H; Li Y; Wang Z; Zhou L; Zhao X; Peng J
    Hematology; 2022 Dec; 27(1):80-87. PubMed ID: 34964431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.
    Manco-Johnson MJ; Soucie JM; Gill JC;
    Blood; 2017 Apr; 129(17):2368-2374. PubMed ID: 28183693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of myofascial release on frequency of joint bleedings, joint status, and joint pain in patients with hemophilic elbow arthropathy: A randomized, single-blind clinical trial.
    Cuesta-Barriuso R; Pérez-Llanes R; Donoso-Úbeda E; López-Pina JA; Meroño-Gallut J
    Medicine (Baltimore); 2021 May; 100(20):e26025. PubMed ID: 34011108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.
    Rossbach HC
    Vasc Health Risk Manag; 2010 Mar; 6():59-68. PubMed ID: 20234780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH.
    Fischer K; Collins PW; Ozelo MC; Srivastava A; Young G; Blanchette VS
    J Thromb Haemost; 2016 May; 14(5):1105-9. PubMed ID: 27186714
    [No Abstract]   [Full Text] [Related]  

  • 31. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.
    Chozie NA; Primacakti F; Gatot D; Setiabudhy RD; Tulaar ABM; Prasetyo M
    Haemophilia; 2019 Jul; 25(4):633-639. PubMed ID: 31044491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country.
    Borhany M; Arshad A; Qureshi H; Nadeem R; Jamal A; Ahmed Khan R
    Clin Appl Thromb Hemost; 2024; 30():10760296231224357. PubMed ID: 38166474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
    Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
    Kavakli K; Yang R; Rusen L; Beckmann H; Tseneklidou-Stoeter D; Maas Enriquez M;
    J Thromb Haemost; 2015 Mar; 13(3):360-9. PubMed ID: 25546368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients.
    Arvanitakis A; Jepsen C; Andersson NG; Baghaei F; Astermark J
    Haemophilia; 2024 May; 30(3):671-677. PubMed ID: 38575549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].
    Sun X; Zhuang J; Zhou X; Li H; Liu Z; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1222-1227. PubMed ID: 30377129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.